DIGIFAB (digoxin immune fab)
DIGOXIN IMMUNE FAB · DIGITALIS TOXICITY
SALVAGENIX INC.
Drug class
Digoxin Immune Fab
Digoxin immune Fab is an antidote and antigen-binding biological agent rather than an expansive therapeutic drug class, representing sterile ovine-derived immunoglobulin fragments targeted against digitalis glycosides. Read more about Digoxin Immune Fab
1 drugs in this class 1 manufacturers
Drugs in Digoxin Immune Fab
Filter & compare in the drug finder →
Opens the drug finder with Digoxin Immune Fab preselected. Add indication or manufacturer filters there.
Digoxin immune Fab is an antidote and antigen-binding biological agent rather than an expansive therapeutic drug class, representing sterile ovine-derived immunoglobulin fragments targeted against digitalis glycosides.
Its primary therapeutic mechanism involves binding free intravascular digoxin with an affinity higher than that of the sodium-potassium ATPase receptor, which pulls tissue-bound drug into the circulation and facilitates renal elimination of the inert Fab-digoxin complex.
Clinically, it is indicated specifically for the acute reversal of severe, life-threatening digoxin or digitoxin toxicity, including critical manifestations such as malignant cardiac arrhythmias, severe refractory hyperkalemia, and massive intentional or accidental overdose.
-
fda.gov
Digoxin immune Fab is an antidote and antigen-binding biological agent rather than an expansive therapeutic drug class, representing sterile ovine-derived immunoglobulin fragments targeted against digitalis glycosides
-
nih.gov
Digoxin immune Fab is an antidote and antigen-binding biological agent rather than an expansive therapeutic drug class, representing sterile ovine-derived immunoglobulin fragments targeted against digitalis glycosides Clinically, it is indicated specifically for the acute reversal of severe, life-threatening digoxin or digitoxin toxicity, including critical manifestations such as malignant cardiac arrhythmias, severe refractory hyperkalemia, and massive intentional or accidental overdose
-
fda.gov
Digoxin immune Fab is an antidote and antigen-binding biological agent rather than an expansive therapeutic drug class, representing sterile ovine-derived immunoglobulin fragments targeted against digitalis glycosides
-
fda.gov
Its primary therapeutic mechanism involves binding free intravascular digoxin with an affinity higher than that of the sodium-potassium ATPase receptor, which pulls tissue-bound drug into the circulation and facilitates renal elimination of the inert Fab-digoxin complex Clinically, it is indicated specifically for the acute reversal of severe, life-threatening digoxin or digitoxin toxicity, including critical manifestations such as malignant cardiac arrhythmias, severe refractory hyperkalemia, a...
-
mims.com
Its primary therapeutic mechanism involves binding free intravascular digoxin with an affinity higher than that of the sodium-potassium ATPase receptor, which pulls tissue-bound drug into the circulation and facilitates renal elimination of the inert Fab-digoxin complex
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.